EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas

Kenichiro Ishikawa, Hiroyuki Suzuki iD, Tomokazu Ohishi iD, Guanjie Li iD, Tomohiro Tanaka, Manabu Kawada iD, Akira Ohkoshi iD, Mika K Kaneko iD, Yukio Katori, Yukinari Kato iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kenichiro Ishikawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan. Hauptthemen laut MEDLINE: Hyaluronan Receptors, Mouth Neoplasms, Antibodies, Monoclonal, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v) isoforms. Since the expression of CD44v is restricted in epithelial cells and carcinomas compared to CD44s, CD44v has been considered a promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C44Mab-18 (IgM, kappa), to recognize the variant exon 10-encoded region. In the present study, a mouse IgG2a version of C44Mab-18 (C44Mab-18-mG2a) was generated to evaluate the antitumor activities against CD44-positive cells compared with the previously established anti-pan CD44 mAb, C44Mab-46-mG2a. C44Mab-18-mG2a exhibited higher reactivity compared with C44Mab-46-mG2a to CD44v3–10-overexpressed CHO-K1 (CHO/CD44v3–10) and oral squamous cell carcinoma cell lines (HSC-2 and SAS) in flow cytometry. C44Mab-18-mG2a exerted a superior antibody-dependent cellular cytotoxicity (ADCC) against CHO/CD44v3–10. In contrast, C44Mab-46-mG2a showed a superior complement-dependent cytotoxicity (CDC) against CHO/CD44v3–10. A similar tendency was observed in ADCC and CDC against HSC-2 and SAS. Furthermore, administering C44Mab-18-mG2a or C44Mab-46-mG2a significantly suppressed CHO/CD44v3–10, HSC-2, and SAS xenograft tumor growth compared with the control mouse IgG2a. These results indicate that C44Mab-18-mG2a could be a promising therapeutic regimen for CD44v10-positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyaluronan ReceptorsMouth NeoplasmsAntibodies, MonoclonalXenograft Model Antitumor AssaysCarcinoma, Squamous CellAnimalsMiceHumansCell Line, TumorCHO CellsCricetulusAntineoplastic Agents, ImmunologicalAntibody-Dependent Cell CytotoxicityCell ProliferationMice, Inbred BALB C

Stichwörter der Autor:innen

ADCCCD44v10CDCmonoclonal antibody therapyoral cancer

Substanzen

Hyaluronan ReceptorsAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
  • Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi 410-0301, Shizuoka, Japan.
  • Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan.

ORCID-Profile: Hiroyuki Suzuki, Tomokazu Ohishi, Guanjie Li, Manabu Kawada, Akira Ohkoshi, Mika K Kaneko, Yukinari Kato

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Ishikawa, K., Suzuki, H., Ohishi, T., Li, G., Tanaka, T., Kawada, M., Ohkoshi, A., Kaneko, M. K., Katori, Y., & Kato, Y. (2024). Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179190

Vancouver

Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, et al. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179190

BibTeX
@article{Ishikawa2024,
  author = {Ishikawa, Kenichiro and Suzuki, Hiroyuki and Ohishi, Tomokazu and Li, Guanjie and Tanaka, Tomohiro and Kawada, Manabu and Ohkoshi, Akira and Kaneko, Mika K and Katori, Yukio and Kato, Yukinari},
  title = {Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179190}
}
Kostenlos starten →